20 articles
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
STAR-FACS technique enables researchers to isolate and study rare cancer cells with specific mutations, revealing how genetic changes drive tumor behavior.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Leukemic stem cells produce their own ketone bodies to block ferroptosis, revealing a metabolic weak point that could be targeted therapeutically.
Researchers identify four LSC subtypes that predict venetoclax resistance and reveal matched subtype-specific therapies for AML patients.
A novel immune-evasion mechanism in triple-negative breast cancer reveals how cancer stem cells suppress anti-tumor immunity via extracellular vesicles.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells β and show bortezomib can fix it in CAR-T therapy.
Scientists used precise gene editing to enhance CAR-T cell therapy, creating more effective and persistent cancer treatments.
A sweeping review of CAR-T and CAR-NK cell therapies in acute myeloid leukemia, covering clinical trial outcomes, key targets, and next-gen strategies.
Scientists discover that maintaining proteostasis in tumor-infiltrating lymphocytes prevents exhaustion and boosts immunotherapy outcomes.
Editorial expression of concern raised for influential 1999 research on creating human tumor cells with defined genetic elements.
Engineered immune cell vesicles first induce cancer cell senescence with chemo, then eliminate them with targeted senolytic drugs.
BCG therapy for bladder cancer travels to bone marrow, reprogramming stem cells to produce enhanced immune cells that fight tumors throughout the body.
MIT researchers identify oncofetal cell states in colorectal tumors that mimic embryonic intestines and prime cancer cells for invasion.
New research reveals how tiny cellular packages from aging cells might be engineered to deliver targeted cancer treatments.
Mechanical tension in the tumor microenvironment controls iron metabolism and cell death susceptibility via a novel NCOA4-FTH1 autophagy axis.
Study identifies blood markers that distinguish long-term survivors from short-term survivors in brain cancer treatment.
A landmark Cell study reveals that the patient's own immune systemβnot just CAR T cellsβdecides outcomes in recurrent glioblastoma.
Cancer cells that downregulate SMC4 enter a low-proliferation, diapause-like state that resists standard chemotherapy, revealing a dangerous survival mechanism.
A phase 1 trial shows Temferon β a gene-engineered stem cell therapy β safely delivers interferon-Ξ± into glioblastoma tumors with no dose-limiting toxicities.
